Natera, Inc. (NASDAQ:NTRA) Shares Acquired by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D grew its position in Natera, Inc. (NASDAQ:NTRA – Get Rating) by 8.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 54,323 shares of the medical research company’s stock after purchasing an additional 4,076 shares during the period. State of New Jersey Common Pension Fund D owned approximately 0.06% of Natera worth $2,210,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. grew its holdings in Natera by 7.5% during the fourth quarter. JPMorgan Chase & Co. now owns 5,079,091 shares of the medical research company’s stock worth $474,337,000 after acquiring an additional 355,574 shares during the period. State Street Corp grew its holdings in Natera by 12.6% during the fourth quarter. State Street Corp now owns 1,829,822 shares of the medical research company’s stock worth $170,887,000 after acquiring an additional 204,621 shares during the period. Marshall Wace LLP grew its holdings in Natera by 33.5% during the fourth quarter. Marshall Wace LLP now owns 1,815,919 shares of the medical research company’s stock worth $169,589,000 after acquiring an additional 456,158 shares during the period. American Century Companies Inc. grew its holdings in Natera by 6.8% during the fourth quarter. American Century Companies Inc. now owns 1,284,116 shares of the medical research company’s stock worth $119,924,000 after acquiring an additional 81,658 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Natera by 3.3% during the fourth quarter. Geode Capital Management LLC now owns 1,127,087 shares of the medical research company’s stock worth $105,258,000 after acquiring an additional 36,243 shares during the period. 96.24% of the stock is owned by institutional investors and hedge funds.

Natera Stock Performance

NASDAQ NTRA opened at $48.99 on Thursday. The company has a market cap of $4.72 billion, a PE ratio of -8.33 and a beta of 1.33. The stock’s 50 day simple moving average is $39.80 and its 200-day simple moving average is $45.61. Natera, Inc. has a 1-year low of $26.10 and a 1-year high of $129.09. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.24 and a quick ratio of 4.13.

Natera (NASDAQ:NTRA – Get Rating) last released its earnings results on Thursday, May 5th. The medical research company reported ($1.45) earnings per share for the quarter, beating the consensus estimate of ($1.50) by $0.05. Natera had a negative return on equity of 96.99% and a negative net margin of 81.90%. The business had revenue of $194.13 million for the quarter, compared to the consensus estimate of $176.61 million. During the same quarter last year, the business posted ($0.74) earnings per share. The business’s quarterly revenue was up 27.5% compared to the same quarter last year. As a group, equities research analysts anticipate that Natera, Inc. will post -5.78 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on NTRA shares. Cowen dropped their target price on Natera from $110.00 to $100.00 in a report on Friday, May 6th. Stephens assumed coverage on Natera in a research report on Monday, April 25th. They set an “overweight” rating and a $54.00 price target on the stock. Piper Sandler lowered their price target on Natera from $75.00 to $60.00 and set a “na” rating on the stock in a research report on Sunday, May 15th. StockNews.com upgraded Natera to a “sell” rating in a research report on Monday, May 9th. Finally, Robert W. Baird lowered their price target on Natera from $100.00 to $71.00 in a research report on Friday, May 6th. One analyst has rated the stock with a sell rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $92.50.

Insider Activity at Natera

In related news, CEO Steven Leonard Chapman sold 1,652 shares of the stock in a transaction that occurred on Thursday, June 23rd. The stock was sold at an average price of $35.76, for a total value of $59,075.52. Following the completion of the sale, the chief executive officer now owns 64,777 shares of the company’s stock, valued at $2,316,425.52. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Natera news, Chairman Matthew Rabinowitz bought 219,820 shares of the business’s stock in a transaction on Thursday, May 12th. The stock was bought at an average price of $28.74 per share, with a total value of $6,317,626.80. Following the completion of the purchase, the chairman now directly owns 420,000 shares in the company, valued at $12,070,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Steven Leonard Chapman sold 1,652 shares of the firm’s stock in a transaction on Thursday, June 23rd. The stock was sold at an average price of $35.76, for a total value of $59,075.52. Following the sale, the chief executive officer now directly owns 64,777 shares of the company’s stock, valued at approximately $2,316,425.52. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 13,966 shares of company stock valued at $550,755. 10.27% of the stock is currently owned by insiders.

Natera Company Profile

(Get Rating)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Want More Great Investing Ideas?

Receive News & Ratings for Natera Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Natera and related companies with MarketBeat.com’s FREE daily email newsletter.

This article was originally published by Etfdailynews.com. Read the original article here.